SIBIONICS
Innovating for You: Revolutionizing Diabetes Care with Every Step.
Since our founding in 2015, SIBIONICS has been at the forefront of transforming diabetes management. Born from a commitment to innovation and a profound understanding of the everyday challenges faced by those with diabetes, we've consistently aimed to redefine the landscape of Continuous Glucose Monitoring (CGM) systems. By merging cutting-edge technology with designs centered around the user, we deliver solutions that not only meet needs but exceed expectations.
Today, with over 1,000,000 users across the globe, SIBIONICS stands as a beacon of reliability and innovation in diabetes care. Our global presence is a testament to the effectiveness of our CGM solutions and our dedication to making a significant, positive impact worldwide.
Looking ahead, SIBIONICS is committed to continuing our legacy of innovation. We're not just keeping pace; we're setting the pace—constantly pushing the boundaries of what's possible in CGM technology and striving for excellence with each new product we introduce.
Forny underliggende teknologier til at tjene folkesundheden
Vi fokuserer på sundhedsstyringsbehovene for den mest omfattende befolkning og bekymrer os også om sygdomsdiagnostik og terapeutiske regimer for populationer med sjældne sygdomme. Vi har integreret et fremragende videnskabsmandsteam til løbende at omdanne banebrydende videnskabelige forskningsresultater til medicinske produkter og tjene folkesundheden.
Teknologisk indsigt i det ukendte vækker potentiale for liv
Baseret på patientbehov introducerer vi biokemi, chipdesign, kunstig intelligens, automatisering og andre teknologier for at få indsigt i de ukendte områder af sundhedsdata og hjælpe mennesker med at foretage ændringer i retning af en bedre livskvalitet
Certifikater
Vi er dedikerede til at hjælpe kunder med at forbedre produktkvaliteten og løse udfordringer.
Milepæle og produktsortiment
2023
The GS1 CGM system received the CE mark for entering the European market.
2021
The continuous glucose monitoring system (CGM) was submitted to National Medical Products Administration for registration and was approved. The practicing license of Yinchuan Sibionics Internet Hospital was approved.
2020
AI-DR was approved as the first Class III medical device for AI-assisted fundus disease diagnosis software in China. Sibionics was certified as National High-tech Enterprise.
2019
Fundus camera obtained the registration certificate for Class II medical device. R&D of capsule endoscopy project was started.
2016
R&D of continuous glucose monitoring system (CGM) was started. R&D of diabetic retinopathy AI-assisted diagnosis software (AI-DR) was started.
2015
Sibionics was established, and American R&D Center was established. R&D of artificial retina project was started.